Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Pharmacotherapy of osteoarthritis
Autore:
Steinmeyer, J;
Indirizzi:
Univ Giessen Klinikum, Orthopad Klin, D-35385 Giessen, Germany Univ Giessen Klinikum Giessen Germany D-35385 , D-35385 Giessen, Germany
Titolo Testata:
ORTHOPADE
fascicolo: 11, volume: 30, anno: 2001,
pagine: 856 - 865
SICI:
0085-4530(200111)30:11<856:POO>2.0.ZU;2-V
Fonte:
ISI
Lingua:
GER
Soggetto:
NONSTEROIDAL ANTIINFLAMMATORY DRUGS; GASTROINTESTINAL TOXICITY; RHEUMATOID-ARTHRITIS; KNEE OSTEOARTHRITIS; CONTROLLED TRIAL; RECOMMENDATIONS; CORTICOSTEROIDS; ACETAMINOPHEN; MANAGEMENT; NAPROXEN;
Keywords:
osteoarthritis; pharmacotherapy; drugs;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
32
Recensione:
Indirizzi per estratti:
Indirizzo: Steinmeyer, J Univ Giessen Klinikum, Orthopad Klin, Paul Meimberg Str 3, D-35385 Giessen, Germany Univ Giessen Klinikum Paul Meimberg Str 3 Giessen Germany D-35385
Citazione:
J. Steinmeyer, "Pharmacotherapy of osteoarthritis", ORTHOPADE, 30(11), 2001, pp. 856-865

Abstract

Osteoarthritis is one of the most common and economically important chronic diseases amongst adults, especially those of a senior age. There now exists a range of effective medications, which either alone or in combination can alleviate the symptoms of the disease and improve the quality of life. Because these medications are not always sufficiently effective and must sometimes be interrupted due to side effects, a large arsenal of active agentsis necessary. Alleviation of pain and inhibition of inflammation are the primary goals of pharmacotherapy,whereby the objective is to return an active or transiently painful, decompensated osteoarthritis to a latent (silent,pain-free) condition. This therapeutic goal can almost always be accomplished by using analgesics, nonsteroidal anti-inflammatory drugs (NSAIDs), or intraarticular injection of glucocorticoids. The main problem in administering NSAIDs is their gastrointestinal toxicity for which a prophylactic medication (e.g., simultaneous application of misoprostol or switching to a COX-2 selective NSAID) should be considered especially with risk groups. The newly developed COX-2 selective NSAIDs represent a true enrichment of our therapeutic options. The spectrum of indications for COX-2 selective NSAIDs should in the future correspond to that of older NSAID preparations, providing that no as yet unknown and serious side effects come to light from their use. Pharmacological results published until now confirm that a clinically relevant analgesic and/or anti-inflammatory effect is associated with the use of SYSA-DOAs (symptomatic slow acting drugs in osteoarthritis). However no clinical studies exist which can positively confirm prevention of morphologically recognizable cartilage defects in man,or a slowing down or reversal of any progressively developing joint cartilage destruction by any individual medication. Neither the benefits, risks, pharmaceutical quality, nor composition of Orthokin((R)) are known, and for this reason its use can not be recommended. Pharmacotherapy should only be considered as one of the three pillars of a long-term, stage-adjusted, and individually customized therapy the other two of which are represented by nonpharmacological measures and surgical treatment.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 31/03/20 alle ore 16:32:09